Comparison of the effects of two different doses of Filgrastim in febrile neutropenia management in childhood malignancy: A randomized clinical trial

N. Mirbehbahani, S. Bagheri, G. Roshandel, A. Jahazi, A. Rashidbaghan
{"title":"Comparison of the effects of two different doses of Filgrastim in febrile neutropenia management in childhood malignancy: A randomized clinical trial","authors":"N. Mirbehbahani, S. Bagheri, G. Roshandel, A. Jahazi, A. Rashidbaghan","doi":"10.18502/ijpho.v12i3.10057","DOIUrl":null,"url":null,"abstract":"Background: Febrile neutropenia (FN) is most often caused due to chemotherapy. Solid or certain lymphoproliferative malignancies can increase the duration of hospitalization and other complications in cancer patients. Filgrastim is used in childhood FN management. This study aimed to compare the effect of two different doses of Filgrastim on hematological and paraclinical factors in hospitalized febrile neutropenic patients with cancer.  \nMaterials and methods: In this randomized clinical trial, 60 febrile neutropenic patients with cancer complying with the inclusion criteria were assigned to both groups A and B. Thirty patients in group A received Filgrastim 5μg/kg/day whereas 30 others in group B received Filgrastim 15μg/kg/day. Hematological factors, physical examination findings, antibiotic administration period, and type of malignancy were then recorded. Complete blood count with differential (CBC diff) was also tested. Lung infiltration was examined by chest X-ray (CXR), and the spleen and abdomen were monitored by ultrasound. \nResults: The mean age of patients was 6 ± 3 years old. The most prevalent malignancies included acute lymphoblastic leukemia (ALL) (35.0%), neuroblastoma (18.3%), osteosarcoma (11.7%), acute myeloid leukemia (AML) (8.3%), and Rhabdomyosarcoma (8.3%). The frequency distribution of malignancies significantly differed between the two groups (P= .01). Changes in hematological factors, including white blood cells (WBC), mature neutrophil cells, and absolute neutrophil count (ANC) in group A, appeared lower than those in the other group. However, none of the studied factors, including hematological factors, physical examination findings, and antibiotic administration period, were found to differ significantly between the two groups (P> 0.05). \nConclusion: Much as a higher dose of Filgrastim seems to bear a better effect on ANC, no significant difference was identified between the two groups. Further studies should be designed with a larger population to address the issue. ","PeriodicalId":129489,"journal":{"name":"Iranian Journal of Pediatric Hematology & Oncology","volume":"47 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pediatric Hematology & Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijpho.v12i3.10057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Febrile neutropenia (FN) is most often caused due to chemotherapy. Solid or certain lymphoproliferative malignancies can increase the duration of hospitalization and other complications in cancer patients. Filgrastim is used in childhood FN management. This study aimed to compare the effect of two different doses of Filgrastim on hematological and paraclinical factors in hospitalized febrile neutropenic patients with cancer.  Materials and methods: In this randomized clinical trial, 60 febrile neutropenic patients with cancer complying with the inclusion criteria were assigned to both groups A and B. Thirty patients in group A received Filgrastim 5μg/kg/day whereas 30 others in group B received Filgrastim 15μg/kg/day. Hematological factors, physical examination findings, antibiotic administration period, and type of malignancy were then recorded. Complete blood count with differential (CBC diff) was also tested. Lung infiltration was examined by chest X-ray (CXR), and the spleen and abdomen were monitored by ultrasound. Results: The mean age of patients was 6 ± 3 years old. The most prevalent malignancies included acute lymphoblastic leukemia (ALL) (35.0%), neuroblastoma (18.3%), osteosarcoma (11.7%), acute myeloid leukemia (AML) (8.3%), and Rhabdomyosarcoma (8.3%). The frequency distribution of malignancies significantly differed between the two groups (P= .01). Changes in hematological factors, including white blood cells (WBC), mature neutrophil cells, and absolute neutrophil count (ANC) in group A, appeared lower than those in the other group. However, none of the studied factors, including hematological factors, physical examination findings, and antibiotic administration period, were found to differ significantly between the two groups (P> 0.05). Conclusion: Much as a higher dose of Filgrastim seems to bear a better effect on ANC, no significant difference was identified between the two groups. Further studies should be designed with a larger population to address the issue. 
两种不同剂量非格昔汀治疗儿童恶性肿瘤发热性中性粒细胞减少症的疗效比较:一项随机临床试验
背景:发热性中性粒细胞减少症(FN)多由化疗引起。实性或某些淋巴增生性恶性肿瘤可增加癌症患者的住院时间和其他并发症。非格拉西汀用于儿童FN治疗。本研究旨在比较两种不同剂量非格昔汀对住院发热性中性粒细胞减少癌患者血液学和临床旁因素的影响。材料与方法:将60例符合纳入标准的发热性中性粒细胞减少的癌症患者随机分为A组和B组,A组30例给予非格拉西汀5μg/kg/d, B组30例给予非格拉西汀15μg/kg/d。然后记录血液学因素、体格检查结果、抗生素给药时间和恶性肿瘤类型。同时检测全血细胞计数(CBC diff)。胸部x线检查肺浸润,超声检查脾、腹部。结果:患者平均年龄6±3岁。最常见的恶性肿瘤包括急性淋巴细胞白血病(ALL)(35.0%)、神经母细胞瘤(18.3%)、骨肉瘤(11.7%)、急性髓性白血病(AML)(8.3%)和横纹肌肉瘤(8.3%)。两组恶性肿瘤的频率分布差异有统计学意义(P= 0.01)。血液学因子的变化,包括白细胞(WBC),成熟中性粒细胞,绝对中性粒细胞计数(ANC)在A组出现低于其他组。血液学因素、体格检查结果、抗生素给药时间等因素在两组间均无显著差异(P> 0.05)。结论:虽然高剂量的非格昔汀似乎对ANC有更好的效果,但两组之间没有明显差异。应该设计更多人口的进一步研究来解决这个问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信